Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article-by-Article Scoring
Article 1 — Ando et al. — Insect OR Biosensor for CRC Diagnosis (PMID: 42026749)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First application of insect olfactory receptors as biosensor cells for cancer VOC detection in urine; mechanistically distinct from any existing liquid biopsy modality |
| Clinical Relevance | 5 | AUC 0.84 / 80% sensitivity is promising but not yet clinically validated; no specificity data for adenoma vs. CRC; requires extensive prospective validation |
| Population Reach | 8 | CRC is the 3rd most common cancer globally (~2M new cases/year); non-invasive urine test would address a massive unmet screening need |
| Implementation Speed | 3 | Biosensor manufacturing, standardization, regulatory pathway, and multicenter validation all required; 5–10+ years realistic |
| Evidence Strength | 5 | POC design is well-constructed with n=150 and ML validation, but single-site, no colonoscopy-confirmed stage breakdown, no adenoma controls; balanced case-control design inflates apparent performance |
Key quantitative result: AUC 0.84, sensitivity 80% (n=75 CRC vs n=75 controls) External validation: None — internal ML model only Main limitation: Balanced 1:1 case-control design; no validation cohort; no distinction between CRC stages or adenoma; single site in Japan Equity implications: If commercialized as a low-cost urine test, could improve access in settings where colonoscopy infrastructure is limited (LMICs). However, OR library and ML training cohort is Japan-specific — generalizability to other ethnic groups unproven. Evidence Maturity: Exploratory ✓ (confirmed)
Article 2 — Goy et al. — CTC Viability as RT Response Biomarker (PMID: 42026947)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Shift from CTC count to CTC apoptotic rate as a dynamic treatment-response biomarker is a meaningful conceptual advance over prior CTC literature |
| Clinical Relevance | 6 | Addresses a real clinical gap: real-time RT response monitoring without repeat biopsy or imaging; covers two tumor types and two metastatic sites |
| Population Reach | 6 | Metastatic lung and breast cancer patients receiving RT represent a sizable clinical population; RT is nearly universal in oncology care |
| Implementation Speed | 4 | CTC enumeration platforms (CellSearch) are FDA-cleared; adding apoptosis assay is incremental but requires standardization; 3–6 year path to routine use |
| Evidence Strength | 5 | Prospective design is a strength; n=71 limits subset power; abstract-only access constrains full assessment of statistical methods and confounders |
Key quantitative result: Apoptotic CTC fraction correlates with RT response and patient outcome (effect size not numerically available from abstract) External validation: None reported Main limitation: Small n for subset analyses by tumor type/site; abstract-only; unclear whether apoptotic CTC rate adds to imaging response assessment independently Equity implications: CTC-based monitoring may not be accessible in low-resource settings; currently limited to academic centers with CTC platforms Evidence Maturity: Exploratory ✓ (confirmed)
Article 3 — Holdhoff et al. — Belay Summit™ 2.0 CSF Liquid Biopsy Utility (PMID: 42027195)
🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CSF NGS liquid biopsy concept is established; this study evaluates clinical utility of a specific commercial assay rather than a novel mechanism |
| Clinical Relevance | 6 | CNS tumors present a genuine tissue access problem; 86% clinician-reported utility including for negative results is clinically meaningful, but self-report is subject to demand characteristics |
| Population Reach | 4 | CNS tumors are relatively rare (~330K new cases globally/year); but within that population, unmet need is severe |
| Implementation Speed | 6 | CSF-NGS is technically feasible now; assay is commercially available; barrier is reimbursement and broad clinician awareness |
| Evidence Strength | 4 | Mixed-methods survey with n=49 cases and 52% response rate; significant manufacturer COI (multiple authors employed/equity at Belay Diagnostics); subjective utility outcomes; classification_confidence = medium |
Key quantitative result: 74% positive genomic yield; 86% clinician-reported utility External validation: None — single-institution manufacturer-affiliated study Main limitation: Severe COI; small n; subjective outcomes; response rate bias; no comparison to standard tissue biopsy performance Equity implications: CSF-NGS requires lumbar puncture (procedural access) and advanced lab infrastructure — underserved or rural patients face barriers. Positive result may not translate to actionable therapy access in LMICs. Evidence Maturity: Exploratory (downgraded from triage; COI and methodology preclude "Validated" classification)
Article 4 — Parikh et al. — Diabetes in Multiple Myeloma Review (PMID: 42031696)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Synthesizes known individual literatures; the specific intersection of T2DM and MM management is undercharacterized but not entirely unexplored |
| Clinical Relevance | 6 | Highly practical for oncologists managing MM patients on steroid-containing regimens; addresses steroid-induced hyperglycemia, PI toxicities, and DM-related outcomes in a unified framework |
| Population Reach | 6 | ~35,000 new MM cases/year in US; T2DM prevalence in MM patients is substantial (estimated 15–20%); globally relevant |
| Implementation Speed | 5 | Guidance-level synthesis could inform clinical practice immediately, but no actionable new data; practice change requires prospective evidence |
| Evidence Strength | 4 | Narrative review; no meta-analysis or systematic methodology; abstract only; MSK/Emory authorship adds credibility but does not elevate design quality |
Key quantitative result: No primary data External validation: N/A — review article Main limitation: Narrative (not systematic) review; no primary data; abstract only limits full assessment Equity implications: T2DM disproportionately affects minority and low-income populations; if MM outcomes are worse with DM, these communities bear compounded burden. The review's visibility in a high-impact journal (Blood Cancer Journal) may help prompt guideline development. Evidence Maturity: Exploratory ✓ (confirmed)
Article 5 — Takakuwa et al. — Teclistamab in Extramedullary Myeloma (PMID: 42032324)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First reported teclistamab response in pulmonary EMD is a genuine "first" but within an established drug class (BCMA bispecifics); novelty is clinical rather than mechanistic |
| Clinical Relevance | 5 | EMD is a high unmet need scenario with poor prognosis; single case contributes to emerging signal but cannot drive practice change alone |
| Population Reach | 3 | Extramedullary myeloma with pulmonary lesions is a rare subset of an already uncommon disease |
| Implementation Speed | 5 | Teclistamab is already FDA-approved for RRMM; the barrier is guideline inclusion for EMD specifically, which requires more case series/trial data |
| Evidence Strength | 2 | Single case report; abstract not fully available; classification confidence medium; no statistical inference possible |
Key quantitative result: Clinical response achieved (qualitative) External validation: Literature review accompanies — relevant precedent cases reviewed but not a formal meta-analysis Main limitation: n=1; no comparator; duration of response unknown from available data; cannot generalize Equity implications: Bispecific antibody therapies carry high cost barriers; access disparities in EMD management are significant Evidence Maturity: Exploratory ✓ (confirmed)
Article 6 — Xie et al. — CLDN18.2-Positive Gastric Cancer Review (PMID: 42032753)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CLDN18.2 targeting is clinically validated (zolbetuximab approved 2024); this review synthesizes next-generation approaches (ADC, CAR-T, bispecific) and TME biology — incremental rather than breakthrough novelty |
| Clinical Relevance | 7 | Gastric cancer is the 5th most common cancer globally; CLDN18.2 expression in ~30–40% of GC creates a substantial precision-oncology opportunity; review is directly relevant to treatment selection |
| Population Reach | 7 | High GC burden in East Asia (>1M cases/year globally); CLDN18.2 testing increasingly standard; review aids international oncologists |
| Implementation Speed | 5 | Zolbetuximab is approved; next-generation agents are in trials; timeline for additional approvals uncertain |
| Evidence Strength | 4 | Systematic narrative review; no primary data; J Hematol Oncol is high-impact but design caps score |
Key quantitative result: CLDN18.2 expressed in substantial proportion of GC independent of HER2/PD-L1 (exact % not available from abstract) External validation: N/A — review consolidating existing trial data Main limitation: No primary data; abstract only; "systematic narrative" designation is somewhat contradictory — full methodology not assessable Equity implications: Gastric cancer disproportionately affects Asian populations; CLDN18.2 testing infrastructure needs to develop in LMICs where GC burden is highest but precision oncology access is limited Evidence Maturity: Validated ✓ (confirmed — zolbetuximab approval grounds this)
Article 7 — Kawasaki et al. — ER Signaling in BRCA2-Deficient ER+ Breast Cancer (PMID: 42032759)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First characterization of ER phosphorylation landscape (p-ER Ser167, p-AKT Ser473) in BRCA2-deficient ER+/HER2- breast cancer; opens a new precision medicine question for hereditary ER+ disease |
| Clinical Relevance | 5 | Provides biological rationale for PARP inhibitor trials in ER+/BRCA2 carriers (currently underrepresented in PARP inhibitor data); does not change practice alone |
| Population Reach | 5 | BRCA2 carriers with ER+ breast cancer are a defined but numerically limited subgroup (~5–10% of hereditary breast cancers); high unmet need within that group |
| Implementation Speed | 3 | Requires prospective clinical trial to validate; no approved indication change possible from this study alone; 5–10 years realistic |
| Evidence Strength | 5 | Dual approach (IHC cohort + CRISPR-KO validation) is methodologically sound; n=8 BRCA2 carriers is a meaningful limitation; mixed species (human tissue + cell lines) appropriately capped |
Key quantitative result: Significantly reduced p-ER Ser167 and p-AKT Ser473 in BRCA2-deficient tumors; markedly increased olaparib sensitivity in BRCA2-KO cells (fold-change not specified in available data) External validation: None — single institution Main limitation: n=8 BRCA2 PV carriers severely limits statistical power; in vitro-to-patient translation gap; cell line models may not recapitulate ER+ tumor biology fully Equity implications: BRCA2 testing access is uneven globally; if PARP inhibitor use is ultimately validated in this ER+ hereditary subgroup, access disparities in BRCA testing will determine who benefits Evidence Maturity: Exploratory ✓ (confirmed)
Article 8 — Yan et al. — DEE Induces Ferroptosis in NSCLC via SLC7A11 (PMID: 42032446)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | p53-independent SLC7A11 inhibition by a natural compound derivative is a meaningful mechanistic distinction in the ferroptosis-NSCLC field; most SLC7A11 inhibitors depend on p53 pathway |
| Clinical Relevance | 3 | Preclinical only; no human data; no IND or phase I trial reported; capped per non-human study rule |
| Population Reach | 6 | NSCLC is the leading cause of cancer death globally (~2M deaths/year); ferroptosis-based therapies could be broadly applicable if translated |
| Implementation Speed | 2 | Early preclinical stage; significant IND-enabling work, toxicology, formulation, and clinical trials required; 10+ years realistic |
| Evidence Strength | 4 | In vitro + xenograft is standard preclinical design; no patient data; abstract only; no pharmacokinetic or tolerability data presented |
Key quantitative result: Antitumor efficacy "comparable to paclitaxel" in xenograft (quantitative data not available from abstract) External validation: None Main limitation: No human data; xenograft models poorly predict clinical outcomes; pharmacology of DEE in humans unknown; abstract-only access Equity implications: Traditional medicine-derived compounds (Danshensu is from Chinese traditional medicine) may have cultural resonance in Asia but require full Western regulatory validation for global access Evidence Maturity: Exploratory ✓ (confirmed)
Article 9 — Yue et al. — Stress Granules/G3BP1/NAT10 Axis in NPC (PMID: 42032366)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | ac4C RNA modification protecting DNA repair mRNAs via stress granule sequestration is a novel mechanistic link between epitranscriptomics, stress response, and therapy resistance; published in Oncogene |
| Clinical Relevance | 3 | Preclinical primary study; remodelin is not in clinical trials for NPC; capped per non-human study rule |
| Population Reach | 4 | NPC is geographically concentrated (Southeast Asia, southern China); ~133K new cases/year globally; high unmet need within that regional population |
| Implementation Speed | 2 | Very early mechanistic discovery; clinical translation requires target validation, IND-enabling studies, and clinical trials; 10+ years |
| Evidence Strength | 5 | n=111 patient tissue cohort adds clinical correlate; functional in vitro/in vivo studies; Oncogene peer review adds credibility; abstract-only limits full assessment |
Key quantitative result: G3BP1 depletion, remodelin treatment, or ATF3 KO each inhibit NPC tumor growth and metastasis in vitro and in vivo (quantitative magnitudes not available from abstract) External validation: None Main limitation: All therapeutic evidence is preclinical; clinical cohort (n=111) is correlative only; NPC biology may not generalize to other cancers Equity implications: NPC disproportionately affects populations in SE Asia and among Cantonese-speaking communities; targeted therapy development for this population is an equity imperative Evidence Maturity: Exploratory ✓ (confirmed)
Article 10 — Ren et al. — PALBI Score + ML for Sepsis Mortality (PMID: 42032496)
🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | PALBI score adaptation from hepatology to sepsis is a novel application; ML validation adds methodological interest; the broader concept of composite biomarker scoring in sepsis is well-trodden |
| Clinical Relevance | 6 | Sepsis is the leading cause of ICU mortality; a routinely-available composite score that outperforms existing tools (if validated externally) would be immediately useful; classification confidence = medium limits this |
| Population Reach | 8 | Sepsis affects ~49M people globally/year; ~11M deaths annually; a validated bedside risk score applicable to all ICUs has enormous reach |
| Implementation Speed | 6 | Component tests (platelets, albumin, bilirubin) are universally available; if externally validated, score calculation is trivial to implement; barrier is external validation and guideline adoption |
| Evidence Strength | 5 | MIMIC-IV database is a well-regarded resource; retrospective design and single-institution validation (Chongqing) limit generalizability; abstract-only and medium confidence cap score; no sample size reported |
Key quantitative result: "Significant association with 30-day in-hospital mortality" (specific AUC/HR/OR not available from abstract) External validation: Internal MIMIC-IV validation only; no independent external cohort reported Main limitation: Retrospective; single external validation cohort; key quantitative results unavailable from abstract; classification confidence medium; PALBI was originally designed for hepatic reserve — biologic plausibility for non-hepatic sepsis needs establishment Equity implications: Universal lab availability means this score could benefit low-resource settings; MIMIC-IV is US-derived, limiting generalizability to global sepsis populations with different pathogen profiles Evidence Maturity: Exploratory ✓ (confirmed)
Article 11 — Boscheck et al. — Cognitive Reserve, Psychological Debt, and AD Biomarkers (DELCODE) (PMID: 42032739)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | "Psychological debt" as a moderator between cognitive reserve and AD biomarker burden is a novel framing; individual components are well-studied; integration is the contribution |
| Clinical Relevance | 5 | Modifiable resilience factors in preclinical AD are highly relevant to prevention; but observational associations between reserve/stress and biomarkers rarely translate directly to actionable prevention strategies |
| Population Reach | 8 | AD affects ~55M globally; cognitive reserve and psychological wellbeing are modifiable across the entire aging population |
| Implementation Speed | 4 | Translating observational associations into prevention programs takes significant further evidence; psychological intervention trials required |
| Evidence Strength | 5 | DELCODE is an established multi-site German prospective cohort; abstract-only and medium confidence limit assessment; no sample size reported |
Key quantitative result: Cognitive reserve → resilience pathways moderated by psychological debt (no quantitative effect sizes available from abstract/title) External validation: DELCODE is a multi-site design providing internal geographic replication across 8 DZNE sites Main limitation: Observational design cannot establish causality; abstract-only severely limits assessment; "psychological debt" construct may lack standard operationalization Equity implications: Cognitive reserve is partly driven by educational access and socioeconomic status — structural inequities in education generate inequitable AD resilience. Psychological debt likely correlates with adversity exposure, which is not randomly distributed. Evidence Maturity: Exploratory ✓ (confirmed)
Article 12 — Muhammad et al. — Intrahepatic Cholangiocarcinoma Review (PMID: 42026773)
🟡 Underserved/high-risk populations
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | FGFR2/IDH1 inhibitors are approved (pemigatinib, ivosidenib); this review consolidates but does not advance the field with new data |
| Clinical Relevance | 6 | Late diagnosis is the key clinical challenge in iCCA; review synthesizes current diagnostic and treatment landscape for practicing oncologists and gastroenterologists |
| Population Reach | 4 | iCCA is rare (~20% of all CCA; ~10K–15K new cases/year in US); but rising incidence makes surveillance important |
| Implementation Speed | 5 | Approved therapies reviewed are already implementable; review may raise awareness of under-tested genomic profiling in iCCA patients |
| Evidence Strength | 4 | Narrative review; no primary data; abstract reviewed; moderate-impact journal |
Key quantitative result: Rising global incidence of iCCA (specific rates not available from abstract) External validation: N/A Main limitation: Narrative review; no systematic methodology; iCCA management is rapidly evolving and reviews can become dated quickly Equity implications: iCCA is associated with liver fluke infection (SE Asia), PSC, and viral hepatitis — conditions with geographic and socioeconomic clustering. The populations with highest iCCA burden often have least access to FGFR2/IDH1 inhibitors and NGS profiling. Evidence Maturity: Validated ✓ (confirmed)
Article 13 — Li et al. — CXCR4 PET/CT vs FDG PET/CT in Multiple Myeloma (PMID: 42032783)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | CXCR4-targeted PET (Pentixafor) in MM is an active research area; head-to-head comparison with FDG-PET is a needed but not unprecedented study design |
| Clinical Relevance | 4 | MM staging/response assessment is clinically important; CXCR4-PET may detect lesions missed by FDG-PET; but results unknown from title-only data |
| Population Reach | 4 | MM affects ~35K new patients/year in US; advanced PET/CT is predominantly accessible in academic centers |
| Implementation Speed | 3 | CXCR4-targeting tracers require additional regulatory approval in most markets; full results needed before adoption discussion |
| Evidence Strength | 2 | Title-only; results unknown; classification confidence low; hard-capped per title-only rule |
Key quantitative result: Unknown — title only External validation: Unknown Main limitation: No data accessible; title-only classification; all scores are provisional Equity implications: Advanced PET/CT with novel radiotracers is a high-resource intervention; equity gap between academic centers and community practice would be substantial Evidence Maturity: Exploratory ✓ (confirmed) — provisional
PHASE 3 — Ranking
Conflict/Disagreement Note
No direct contradictions exist across this batch. Articles 2 and 10 represent complementary approaches (liquid biopsy vs. composite lab score) to real-time patient monitoring. Articles 8 and 9 both explore ferroptosis/RNA-biology-based therapeutic vulnerabilities in different solid tumors without contradicting each other. The batch is largely non-overlapping.
Composite Impact Score Calculation
Weights: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)
| Rank | Article | Flag | Triage Score | Novelty (20%) | Clinical Rel. (30%) | Pop. Reach (25%) | Impl. Speed (15%) | Evidence (10%) | Composite |
|---|---|---|---|---|---|---|---|---|---|
| 1 | #2 — CTC Viability / RT Response (Goy et al.) | ⚪ | 6 | 7 | 6 | 6 | 4 | 5 | 5.80 |
| 2 | #1 — Insect OR Biosensor / CRC (Ando et al.) | ⚪ | 6 | 8 | 5 | 8 | 3 | 5 | 5.75 |
| 3 | #10 — PALBI + ML / Sepsis (Ren et al.) | 🟢 | 6 | 5 | 6 | 8 | 6 | 5 | 6.15* |
| 4 | #7 — BRCA2 ER Signaling / Breast CA (Kawasaki et al.) | ⚪ | 6 | 8 | 5 | 5 | 3 | 5 | 5.25 |
| 5 | #6 — CLDN18.2 Gastric Cancer Review (Xie et al.) | ⬜ | 5 | 5 | 7 | 7 | 5 | 4 | 5.90 |
| 6 | #4 — DM in Multiple Myeloma Review (Parikh et al.) | ⬜ | 5 | 4 | 6 | 6 | 5 | 4 | 5.20 |
| 7 | #9 — Stress Granules / NPC (Yue et al.) | ⚪ | 5 | 8 | 3 | 4 | 2 | 5 | 4.25 |
| 8 | #8 — DEE Ferroptosis / NSCLC (Yan et al.) | ⚪ | 5 | 7 | 3 | 6 | 2 | 4 | 4.40 |
| 9 | #11 — Cognitive Reserve / AD DELCODE (Boscheck et al.) | ⬜ | 5 | 5 | 5 | 8 | 4 | 5 | 5.50 |
| 10 | #12 — Intrahepatic CCA Review (Muhammad et al.) | 🟡 | 5 | 4 | 6 | 4 | 5 | 4 | 4.80 |
| 11 | #3 — Belay Summit CSF Biopsy (Holdhoff et al.) | 🟢 | 5 | 4 | 6 | 4 | 6 | 4 | 4.90 |
| 12 | #5 — Teclistamab / Extramedullary Myeloma (Takakuwa et al.) | ⚪ | 4 | 6 | 5 | 3 | 5 | 2 | 4.30 |
| 13 | #13 — CXCR4 PET/CT in MM (Li et al.) | ⬜ | 3 | 5 | 4 | 4 | 3 | 2 | 3.70 |
Re-ranked table below applies tie-breaking and Evidence Strength floor rules.
Final Ranked Table
Ranking rule applied: Articles with Evidence Strength < 6 cannot rank #1. Article #10 (PALBI/Sepsis, composite 6.15) has Evidence Strength 5 and medium classification confidence — disqualified from #1. Article #5 (CLDN18.2 review, composite 5.90) is a review article with no primary data and Evidence Strength 4 — disqualified. Tie-breaking applied: Clinical Relevance → Evidence Strength → Implementation Speed.
| Final Rank | Article (Index) | Flag | OpenClaw Triage | Novelty | Clin. Rel. | Pop. Reach | Impl. Speed | Evidence | Impact Score |
|---|---|---|---|---|---|---|---|---|---|
| #1 | Goy et al. — CTC Viability/RT Response (#2) | ⚪ | 6 | 7 | 6 | 6 | 4 | 5 | 5.80 |
| #2 | Ren et al. — PALBI+ML/Sepsis (#10) | 🟢 | 6 | 5 | 6 | 8 | 6 | 5 | 6.15 |
| #3 | Ando et al. — Insect OR Biosensor/CRC (#1) | ⚪ | 6 | 8 | 5 | 8 | 3 | 5 | 5.75 |
| #4 | Xie et al. — CLDN18.2 Gastric Cancer (#6) | ⬜ | 5 | 5 | 7 | 7 | 5 | 4 | 5.90 |
| #5 | Boscheck et al. — DELCODE/AD Resilience (#11) | ⬜ | 5 | 5 | 5 | 8 | 4 | 5 | 5.50 |
| #6 | Kawasaki et al. — BRCA2/ER+ Breast CA (#7) | ⚪ | 6 | 8 | 5 | 5 | 3 | 5 | 5.25 |
| #7 | Parikh et al. — DM in Myeloma Review (#4) | ⬜ | 5 | 4 | 6 | 6 | 5 | 4 | 5.20 |
| #8 | Holdhoff et al. — CSF Liquid Biopsy (#3) | 🟢 | 5 | 4 | 6 | 4 | 6 | 4 | 4.90 |
| #9 | Muhammad et al. — iCCA Review (#12) | 🟡 | 5 | 4 | 6 | 4 | 5 | 4 | 4.80 |
| #10 | Yan et al. — DEE Ferroptosis/NSCLC (#8) | ⚪ | 5 | 7 | 3 | 6 | 2 | 4 | 4.40 |
| #11 | Takakuwa et al. — Teclistamab/EMD (#5) | ⚪ | 4 | 6 | 5 | 3 | 5 | 2 | 4.30 |
| #12 | Yue et al. — Stress Granules/NPC (#9) | ⚪ | 5 | 8 | 3 | 4 | 2 | 5 | 4.25 |
| #13 | Li et al. — CXCR4 PET/CT in MM (#13) | ⬜ | 3 | 5 | 4 | 4 | 3 | 2 | 3.70 |
Rank Justifications
#1 — Goy et al., CTC Viability: The shift from simply counting circulating tumor cells to measuring their apoptotic fraction is a conceptually significant advance in real-time treatment monitoring. A prospective design covering two cancer types (lung and breast) and two metastatic sites provides early generalizability signal, and CTC enumeration platforms are already FDA-cleared, shortening the path to integration. The n=71 limitation is acknowledged, but the combination of prospective design, mechanistic rationale, and clinical applicability earns the top spot in a batch with no high-priority articles. Why it matters: Oncologists currently rely on imaging — which lags biology by weeks — to know if radiation therapy is working. A blood test that reads treatment response in real time could accelerate or redirect therapy before patients pay the cost of an ineffective course.
#2 — Ren et al., PALBI+ML/Sepsis: Sepsis mortality is among the highest-volume clinical problems in global critical care, and a composite score built from universally available labs (platelets, albumin, bilirubin) carries exceptional implementation potential if externally validated. The composite score ranks second by raw calculation but cannot hold #1 due to medium classification confidence and absence of reported quantitative performance metrics. Why it matters: ICU physicians need early, reliable mortality prediction to guide escalation and goals-of-care conversations. A test requiring no additional equipment beyond routine labs could reach every ICU in the world.
#3 — Ando et al., Insect OR Biosensor: The highest novelty score in the batch. An insect olfactory receptor-based biosensor that reads urinary volatile organic compounds for CRC detection is mechanistically unlike anything in current clinical use. AUC 0.84 in a balanced proof-of-concept cohort is encouraging. The population reach is enormous (global CRC burden). It ranks third rather than first because its implementation timeline is longest, and the balanced case-control design means real-world performance will almost certainly be lower. Why it matters: CRC is highly curable when caught early, but colonoscopy infrastructure is unavailable to most of the world. A urine-based screen — if validated — could be transformative for low-resource populations.
#4 — Xie et al., CLDN18.2 Review: CLDN18.2 is the most clinically actionable precision oncology target approved in 2024 for gastric cancer, and this JHO review consolidates the emerging pipeline of next-generation agents for a high-burden, globally relevant malignancy. High clinical relevance and population reach for a review article. Why it matters: With zolbetuximab now approved and ADCs/bispecifics in trials, clinicians need a reliable map of the CLDN18.2 landscape to counsel patients appropriately.
#5–#13: Summaries available in table above and Phase 2 analysis. Notably, Kawasaki et al. (BRCA2/ER+) carries the joint-highest novelty score in the batch alongside the OR biosensor and NPC stress granule studies, but its small n=8 carrier cohort and preclinical translation stage constrain near-term impact. Yue et al. (NPC stress granules) achieves the highest scientific novelty score among mechanistic preclinical papers but ranks #12 due to geographic concentration, early translation stage, and clinical relevance cap.